Latest News

AstraZeneca to buy Amolyt Pharma for $1.05 bln to improve rare-disease portfolio

Drugmaker AstraZeneca stated on Thursday it would acquire endocrine diseasesfocused company Amolyt Pharma for $1.05 billion in money, in a quote to boost its unusual illness portfolio.

France's Amolyt, backed by financiers consisting of Danish drugmaker Novo Nordisk's parent firm Novo Holdings and EQT Life Sciences, is currently in the late-stage advancement of a treatment for hypoparathyroidism called eneboparatide.

The deal, which includes an $800 million in advance payment and an extra contingent payment of $250 million on accomplishing a. defined regulatory turning point, is expected to nearby the. third quarter of 2024.

Income from AstraZeneca's uncommon illness portfolio, enhanced. by the $39 billion acquisition of Alexion in 2021, has actually swelled. in recent years, to nearly $7.8 billion in 2023.

Eneboparatide, which is expected to be introduced next year,. has hit capacity, Alexion CEO Marc Dunoyer told . in an interview.

Over the near decade since AstraZeneca warded off a takeover. by U.S. competing Pfizer, CEO Pascal Soriot has actually rebuilt the. Anglo-Swedish drugmaker's pipeline, which includes 13. smash hit medicines - those that create more than $1 billion. in yearly sales.

Last month, Soriot said it was a great time for AstraZeneca. do offers, after a string of acquisitions consisting of a licensing. deal late last year that gave it an entry into the growing. anti-obesity drug market.

(source: Reuters)